IL13RA2 and neoplasm: All these findings indicate that IL13Ra2 is a good target for CAR-T-cell therapy and other therapeutics since it leads to the specific killing of cancer cells that are the most resistant to current therapeutics and, thus, the origin of tumor recurrence [57].